axiebet88 app

None

Year in Review: North Carolina’s 24 in 2024- Completed Initial Public Offering (IPO) of common stock, raising gross proceeds of $82.1M - Single Ascending Dose (SAD) portion of Phase 1 study of CMP-CPS-001 completed; safety data anticipated in Q1 2025 - Entered strategic research collaboration with BioMarin valued at over $370M CAMBRIDGE, Mass., Nov. 21, 2024 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels across a range of genetic diseases, today reported financial results for the third quarter ended September 30, 2024, and provided a corporate update. “The third quarter of 2024 has been transformational for CAMP4, highlighted by our successful IPO and continued strong progress with our lead program, CMP-CPS-001, which received Orphan Drug Designation and Rare Pediatric Disease Designation from the FDA, underscoring its potential as a novel therapeutic candidate for the treatment of urea cycle disorders,” said Josh Mandel-Brehm, Chief Executive Officer of CAMP4. “We also partnered with BioMarin to identify novel therapeutics targeting regRNAs associated with genetic diseases, validating the potential of our RNA Actuating Platform and reinforcing our commitment to advance cutting-edge solutions for patients in need.” Mr. Mandel-Brehm continued, “We continue to advance our CMP-CPS-001 program through the Phase 1 trial, and we anticipate reporting SAD safety data in the first quarter of 2025 followed by multiple ascending dose (MAD) biomarker efficacy data in the second half of 2025, that may enable a registrational Phase 2/3 study. With the proceeds from our IPO, we are well positioned to support continued clinical and preclinical development of our ongoing programs.” Recent Corporate Highlights: Third Quarter 2024 Financial Results CAMP4 ended the third quarter with $2.5 million in cash and cash equivalents. On a pro forma basis, considering the $82.1M IPO proceeds, the company is well positioned to support continued growth and the development of its ongoing programs. Research and Development (R&D) expenses were $9.7 million for the third quarter of 2024 compared to $9.8 million for the third quarter of 2023. The decrease was mainly due to a modest reduction in workforce-related expense, offset in part by an increase in lab operation expense and preclinical and clinical consulting fees. General and administrative (G&A) expenses were $3.8 million for the quarter ended September 30, 2024, compared to $2.9 million for the quarter ended September 30, 2023. The increase in G&A expenses was primarily due to an increase in stock-based compensation expense and higher patent-related expenses vs. prior period. Net loss was $13.5 million for the third quarter 2024, compared to $11.7 million for the same period in 2023. About CAMP4 Therapeutics CAMP4 is developing disease-modifying treatments for a broad range of genetic diseases where amplifying healthy protein may offer therapeutic benefits. Our approach amplifies mRNA by harnessing a fundamental mechanism of how genes are controlled. To amplify mRNA, our therapeutic ASO drug candidates target regRNAs, which act locally on transcription factors and are the master regulators of gene expression. CAMP4’s proprietary RAP PlatformTM enables the mapping of regRNAs and generation of therapeutic candidates designed to target the regRNAs associated with genes underlying haploinsufficient and recessive partial loss-of-function disorders, of which there are more than 1,200, in which a modest increase in protein expression may have the potential to be clinically meaningful. Learn more about us at www.CAMP4tx.com and follow us on LinkedIn and X . Forward-Looking Statements This press release contains forward-looking statements which involve risks, uncertainties and contingencies, many of which are beyond the control of the Company, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. All statements other than statements of historical facts contained in this press release are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements include, but are not limited to, statements concerning CAMP4’s plans, objectives, expectations and intentions; the timing and results of ongoing and future clinical trials, including expectations on the timing of reporting SAD and MAD data from and seeking regulatory approval for the CMP-CPS-001 trial; its growth strategy; and cash balance guidance. The forward-looking statements in this press release speak only as of the date of this press release and are subject to a number of known and unknown risks, uncertainties and assumptions that could cause the Company’s actual results to differ materially from those anticipated in the forward-looking statements, including, but not limited to: the Company’s limited operating history, incurrence of substantial losses since the Company’s inception and anticipation of incurring substantial and increasing losses for the foreseeable future; the Company’s need for substantial additional financing to achieve the Company’s goals; the uncertainty of clinical development, which is lengthy and expensive, and characterized by uncertain outcomes, and risks related to additional costs or delays in completing, or failing to complete, the development and commercialization of the Company’s current product candidates or any future product candidates; delays or difficulties in the enrollment and dosing of patients in clinical trials; the impact of any significant adverse events or undesirable side effects caused by the Company’s product candidates; potential competition, including from large and specialty pharmaceutical and biotechnology companies; the Company’s ability to realize the benefits of the Company’s current or future collaborations or licensing arrangements and ability to successfully consummate future partnerships; the Company’s ability to obtain regulatory approval to commercialize any product candidate in the United States or any other jurisdiction, and the risk that any such approval may be for a more narrow indication than the Company seeks; the Company’s dependence on the services of the Company’s senior management and other clinical and scientific personnel, and the Company’s ability to retain these individuals or recruit additional management or clinical and scientific personnel; the Company’s ability to grow the Company’s organization, and manage the Company’s growth and expansion of the Company’s operations; risks related to the manufacturing of the Company’s product candidates, which is complex, and the risk that the Company’s third-party manufacturers may encounter difficulties in production; the Company’s ability to obtain and maintain sufficient intellectual property protection for the Company’s product candidates or any future product candidates the Company may develop; the Company’s reliance on third parties to conduct the Company’s preclinical studies and clinical trials; the Company’s compliance with the Company’s obligations under the licenses granted to the Company by others, for the rights to develop and commercialize the Company’s product candidates; risks related to the operations of the Company’s suppliers; and other risks and uncertainties described in the section “Risk Factors” in the Company’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, as well as other information we file with the Securities and Exchange Commission. The forward-looking statements in this press release are inherently uncertain and are not guarantees of future events. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond the Company’s control, you should not unduly rely on these forward-looking statements. The events and circumstances reflected in the forward-looking statements may not be achieved or occur and actual future results, levels of activity, performance and events and circumstances could differ materially from those projected in the forward-looking statements. Moreover, the Company operates in an evolving environment. New risks and uncertainties may emerge from time to time, and management cannot predict all risks and uncertainties. Investors, potential investors, and others should give careful consideration to these risks and uncertainties. Except as required by applicable law, the Company does not undertake to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Contacts Investor Relations: Sandya von der Weid LifeSci Advisors svonderweid@lifesciadvisors.com Media: Jason Braco, Ph.D. LifeSci Communications jbraco@lifescicomms.com (1) Working capital is defined as total current assets less total current liabilities. See our condensed consolidated financial statements and the related notes thereto included in our Quarterly Report on Form 10-Q for the period ended September 30, 2024 for further details regarding our current assets and current liabilities.Ranked: Morocco, Nigeria lead the most valuable countries that qualified for AFCON 2025

SANTA CLARA, Calif. (AP) — When the San Francisco 49ers used a third-round pick to draft Jake Moody last year, the hope was it would settle their kicking position for years to come. A shaky second half to Moody's second season with San Francisco has put that into question headed to the offseason. Moody missed his sixth field goal in the past seven games last week, leading to questions about whether the 49ers will need to replace him or at least bring in competition for next season. Coach Kyle Shanahan expressed confidence in Moody on Thursday, attributing some of the struggles to a high ankle sprain he suffered in his kicking leg earlier in the season. “I still feel the same about him, that I believe he is going to be our guy," Shanahan said. “Everyone has got to perform and do things like that and I think he has had a tough year. ... I thought he was doing really well and then had a high ankle sprain to his kicking foot. Since he’s come back, he hasn’t been as consistent, obviously. But I think a lot of that probably has to do with that, just common-sense wise.” Moody got off to a strong start this season, making all six field goals he attempted in the season opener and going 13 for 14 before injuring his ankle while attempting to make a tackle on a kickoff return in Week 5. He missed three games and has struggled since he returned. He missed three field goals in first first game back at Tampa Bay, two more in the snow at Buffalo in Week 13 and then a 41-yarder last week against the Dolphins. “That’s the great thing about kicking is, you can be as talented as whoever and you can struggle,” Moody said. “I feel like this year, I’ve struggled. It doesn’t really waver my confidence or anything. I feel like, throughout my entire life, I’ve gone through struggles, I’ve gone through high points. The biggest thing is to just stay consistent, not change anything.” Moody had an up-and-down rookie season, making 21 of 25 field goals in the regular season and missing only one extra point. But he missed a potential game-winning kick in a loss at Cleveland and missed field goals in playoff wins against Green Bay and Detroit. Moody then made three field goals in the Super Bowl with two coming from more than 50 yards, including a go-ahead 53-yard kick late in the fourth quarter against Kansas City. But Moody also had an extra point blocked in that game. “I believe we’ve got the right guy and I think that eventually, I think he has shown that at times,” Shanahan said. "I thought he showed that at times his rookie year. I thought he showed that big time being 12 out of 13 to start this year. And I think he’ll show us all that in the future.” NOTES: The Niners placed LT Trent Williams on IR after his ankle injury hasn't healed as quickly as hoped. Shanahan didn't think there were any long-term issues. ... LB Dre Greenlaw (calf) will be shut down for the rest of the season after playing parts of two games in his return from a torn left Achilles tendon. ... OL Spencer Burford (calf) didn't practice but might be able to play this week. ... San Francisco has signed two OL this week, adding Matt Hennessy and Charlie Heck. ... RB Isaac Guerendo (hamstring, foot) was limited but appears on track to play this week. AP NFL: https://apnews.com/hub/NFLThe American Athletic Conference is the only Football Bowl Subdivision league whose championship game matchup is set: Army vs. Tulane. The final week of the regular season will determine pairings for the other eight conferences. Here's a look at the possible matchups in the Power Four and Group of Five. All championship games are Dec. 7 except in the AAC, Conference USA and Mountain West, which will be played Dec. 6. SMU vs. Miami or Clemson. Miami is in if it beats Syracuse. Clemson is in if Miami loses. Oregon vs. Ohio State, Penn State or Indiana. Ohio State is in if it beats Michigan or if Penn State and Indiana lose this week. Penn State is in if it beats Maryland and Ohio State loses. Indiana is in if it beats Purdue and Ohio State and Penn State lose. Arizona State vs. Iowa State if both win this week. Multiple scenarios including BYU, Colorado and other teams exist otherwise. Georgia vs. winner of Texas-Texas A&M game. Army vs. Tulane. Jacksonville State vs. Liberty, Western Kentucky or Sam Houston. Liberty is in with a win over Sam Houston. WKU is in with a win over Jacksonville State and a Liberty loss. Sam Houston is in with a win over Liberty and a Jacksonville State win. Miami, Bowling Green and Ohio are tied for first place and control their destinies. Miami-Bowling Green winner is in, as is Ohio if it beats Ball State. Other scenarios exist that include those teams and Buffalo. Boise State vs. UNLV or Colorado State. If UNLV and CSU both win or lose their final regular-season games, the tie would be broken by either College Football Playoff rankings or results-based computer metrics. Louisiana-Lafayette at Marshall if both win their games this week. Other scenarios exist if one or both lose. Get poll alerts and updates on the AP Top 25 throughout the season. Sign up here . AP college football: https://apnews.com/hub/ap-top-25-college-football-poll and https://apnews.com/hub/college-football

NoneFinal regular-season games loom large in determining conference championship matchupsThe Duke Blue Devils versus the Kansas State Wildcats is one of eight games on Monday’s college basketball slate that features a ranked team in play. Watch women’s college basketball, other live sports and more on Fubo. What is Fubo? Fubo is a streaming service that gives you access to your favorite live sports and shows on demand. Use our link to sign up for a free trial. Catch tons of live women’s college basketball , plus original programming, with ESPN+ or the Disney Bundle.

Packers CB Jaire Alexander has been playing with a torn PCL

A new independent report reveals that medication management solutions like Ochsner Digital Medicine deliver superior hypertension outcomes and long-term cost savings compared to other digital approaches NEW ORLEANS , Nov. 25, 2024 /PRNewswire/ -- A groundbreaking evaluation by the Peterson Health Technology Institute (PHTI) has identified that digital hypertension solutions centered on medication management deliver rapid and clinically meaningful improvements in blood pressure that outperform traditional care. The report also found that other digital approaches to hypertension management focused only on patient behavior change and transmitting home monitoring data to providers are less effective, and do not provide clinically meaningful improvements. Among the standout solutions with clinically effective medication management at its core is Ochsner Digital Medicine , a digital platform that integrates cutting-edge technology to improve patient outcomes. "Unlike other programs that simply monitor health conditions, Ochsner Digital Medicine offers comprehensive care, including adjusting medications to find the right treatment, health coaching, and managing conditions with specialized clinicians," said Dan Shields , CEO of Ochsner Digital Medicine. "The program was designed and is delivered by a leading academic health system, and studies like this show it gets better results than traditional care models." Hypertension, a prevalent chronic condition affecting nearly half of U.S. adults, incurs an annual economic burden of $131 billion . Addressing this silent menace demands innovative approaches that transcend conventional care. According to PHTI's findings, digital solutions that emphasize medication management not only offer immediate clinical benefits but also promise long-term cost savings. These savings stem from a reduction in costly utilizations such as unnecessary emergency department visits and inpatient admissions, as well as mitigating risks associated with strokes and heart attacks. Ochsner Digital Medicine has emerged as a leader in the medication management category, exemplifying how integrating connected blood pressure cuffs with expert virtual care from licensed clinicians can usher in a new era of hypertension management. This approach both optimizes clinical outcomes and supports healthcare providers in delivering timely and personalized care. "Too many people are living with uncontrolled hypertension, but there are effective digital solutions to help patients improve their cardiovascular health, save lives, and lower spending over the long run," Caroline Pearson , Executive Director of PHTI, said in a press release. "Digital medication management solutions support healthcare providers with virtual teams to monitor blood pressure and adjust medications to help bring patients into control within months rather than years." The report advocates for the broader adoption of medication management-based digital solutions, urging healthcare purchasers to consider long-term health benefits and cost-effectiveness when incorporating these technologies. PHTI's comprehensive analysis categorized digital hypertension solutions into three categories: The report findings were that blood pressure monitoring and behavior change interventions led to small, non-significant reductions in systolic blood pressure compared with usual care, while medication management resulted in more rapid and clinically meaningful SBP reductions with higher evidence certainty. PHTI's evaluation is based on a rigorous assessment framework, considering clinical efficacy, economic impact, and health equity. By reviewing 2,498 articles and collaborating with experts across health technology, economics, cardiology, and endocrinology, PHTI provides a robust endorsement of these innovative solutions. In an era where healthcare innovation is paramount, Ochsner Digital Medicine stands at the forefront, leveraging digital technology to transform hypertension care and ensure better health outcomes for millions. "We aren't just about monitoring health conditions, we're about comprehensive, unwavering clinical excellence. That is our commitment to our patients," said Shields. About Ochsner Digital Medicine Ochsner Health is an integrated healthcare system with a mission to Serve, Heal, Lead, Educate and Innovate. Celebrating more than 80 years of service, it leads nationally in cancer care, cardiology, neurosciences, liver and kidney transplants, and pediatrics, among other areas. Ochsner is consistently named both the top hospital and top children's hospital in Louisiana by U.S. News & World Report. Its cutting-edge Connected Health Digital Medicine program cares for patients beyond its walls by applying technology and data to create customized, patient-centered digital health solutions for chronic condition management. This program is a true clinical model that includes medication management by licensed clinicians. It enables members to improve their health and patient experience while reducing costs. Ochsner Digital Medicine is live in all 50 states, serving members, health plans, and employers nationally. Learn more at connectedhealth.ochsner.org/digital-medicine . SOURCE Ochsner HealthNokia Corporation Stock Exchange Release 21 November 2024 at 22:45 EET Nokia completes the share buyback program launched in March Espoo, Finland - Nokia Corporation ("Nokia" or the "Company") has now completed the share buyback program announced on 18 March 2024 and upsized on 19 July 2024. Between 20 March 2024 and 21 November 2024, Nokia repurchased 157,646,220 of its own shares (FI0009000681) at an average price per share of approximately EUR 3.81. Nokia expects to cancel the acquired shares in December 2024. The repurchases under the share buyback program reduced the Company's unrestricted equity by EUR 600 million. Nokia Corporation now holds a total of 209,702,510 treasury shares. The repurchases were executed otherwise than in proportion to the existing shareholdings of Nokia's shareholders (directed repurchases) through public trading on the regulated market of Nasdaq Helsinki and selected multilateral trading facilities. About Nokia At Nokia, we create technology that helps the world act together. As a B2B technology innovation leader, we are pioneering networks that sense, think and act by leveraging our work across mobile, fixed and cloud networks. In addition, we create value with intellectual property and long-term research, led by the award-winning Nokia Bell Labs. With truly open architectures that seamlessly integrate into any ecosystem, our high-performance networks create new opportunities for monetization and scale. Service providers, enterprises and partners worldwide trust Nokia to deliver secure, reliable, and sustainable networks today - and work with us to create the digital services and applications of the future. Inquiries: Nokia Communications Phone: +358 10 448 4900 Email: [email protected] Maria Vaismaa, Global Head of External Communications Nokia Investor Relations Phone: +358 40 803 4080 Email: [email protected]Panthers TE Ja'Tavion Sanders carted off field for neck injuryAfter Fresno Visit, Newsom Announces $24.7M Taxpayer-Funded Apprenticeship Program

Carolina Panthers tight end Ja'Tavion Sanders was taken to a hospital for a neck injury after landing on his head while making a catch late in the first half of Sunday's 30-27 home loss to the Kansas City Chiefs. As Sanders was brought down near the sideline after a 10-yard reception, he was flipped upside down and landed directly on the top of his helmet as he went out of bounds on the tackle by cornerback Trent McDuffie. After receiving attention from the team's medical staff, Sanders was strapped to a backboard and taken off the field on a cart with 40 seconds remaining in the half. He was taken to Atrium Health Carolinas Medical Center in Charlotte for observation and later released Sunday afternoon, according to the team. On the CBS broadcast following halftime, Panthers head coach Dave Canales said Sanders had movement in all his extremities, while extreme precaution was taken because of back tightness. CBS reported he was being examined for a concussion before later amending that to a neck injury. The 21-year-old rookie out of Texas had a team-leading three receptions for the Panthers at the half for 49 yards. In 11 games this season, Sanders has 29 receptions for 302 yards and a touchdown. Sanders was a fourth-round selection in the NFL draft in April. --Field Level Media

With 2024 coming to a close, take a look back at some of the year’s biggest moments with Robin Roberts and other ABC news members. “ The Year: 2024 ” airs Thursday, Dec. 26, at 9 p.m. ET on ABC . Stream the news special for free with a trial from DIRECTV Stream or Fubo , or watch it starting on Dec. 27 with a free Hulu trial or Hulu with the Disney Bundle . “Good Morning America” anchor Robin Roberts hosts a look back at the top stories, trends and entertainment obsessions that defined 2024. The special, now in its 14th year, will include interviews with newsmakers, celebrities and cultural and political contributors. This two-hour special will cover everything from landmark legal decisions and the presidential election to breakout stars and champions that had us tuned to the TV. Interviews will include Elton John, Teddy Swims, Shaboozey, Lisa Ann Walter, Ilona Maher, Stephen Nedoroscik and many more names from an eventful year. Roberts will be joined by “World News Tonight” anchor David Muir, “Good Morning America’s” Michael Strahan and Lara Spencer, “World News Tonight” Sunday anchor Linsey Davis, “Nightline” co-anchor Juju Chang, “20/20” co-anchor Deborah Roberts and ABC News correspondent Will Reeve. Tune in to see what 2024 will be remembered for. “ The Year: 2024 ” airs tonight, Dec. 26, at 9/8c on ABC .

China okays mega dam in Tibet's high seismic zonePanthers TE Ja'Tavion Sanders carted off field for neck injury

GroenLinks-PvdA leader Frans Timmermans sees the VVD increasingly moving towards the PVV. The latest example of this, according to him, is the speech by VVD party leader Dilan Yeşilgöz in which she said she wanted to restrict freedom of education and the role of religion in society. "I do not understand why the VVD, with the history of that party, is so enchanted by an agenda that will only fuel division in this country. That does not make it possible to bridge the differences. That radical rejection of religion is so contrary to the history of our country," said Timmermans at a political members' council of the PvdA in Zwolle. Mensen worden tegen elkaar opgezet. Dat moeten we tegengaan door onderlinge verschillen te verkleinen. Het minimumloon omhoog en iedereen toegang tot zorg. En de échte rotzakken aanpakken: de winstmakers die mensen uitbuiten en profiteren. bij de ledenraad. He also sees no integration problem in the Netherlands. According to him, disintegration is the problem. "What we no longer have is contact between theoretically and practically trained people, what we no longer have is understanding between cities and countryside, what we no longer have is understanding between different population groups. We have lost that." The discussion about integration flared up after the recent riots in Amsterdam in which fans of the Israeli football club Maccabi Tel Aviv were hounded. For example, VVD State Secretary Jurgen Nobel (Integration) concluded after that event that Islamic youth "to a large extent do not subscribe to our Dutch norms and values". Timmermans also does not understand why NSC, as a party that stands up for the rule of law, is still in the Cabinet. The Cabinet has "publicly used words that are discriminatory to say the least". According to him, "this country could go under if we do not put a stop to the disintegration that is being stimulated by the coalition parties and the Cabinet". D66 leader Rob Jetten did not shy away from sharply criticizing the government. During the D66 congress, he pointed out that there was a lack of decisiveness of the Cabinet of PVV, VVD, NSC, and BBB. "Take people's concerns seriously for once. Get to work, or get out of the way," he said at the meeting in Den Bosch. The VVD hopes to finally be able to settle matters with the PVV that had not been possible before. But according to Jetten, that will come to nothing. "The only thing you settle with the PVV is chaos and division. Pieter Omtzigt's NSC stands by and watches. It is something to be ashamed of, so I say to Wilders, Yeşilgöz, and Omtzigt: the problems of the Netherlands will not wait until you have stopped arguing." De coalitie holt van chaos naar chaos. Er is nog niets gepresteerd. Daarom zeg ik tegen Wilders, Yesilgöz en Omtzigt: de problemen van Nederland wachten niet tot jullie zijn uitgeruzied. Neem de zorgen van mensen nu eindelijk eens serieus. Ga aan de slag, of ga aan de kant!... The D66 leader sees the cabinet rushing from "crisis to crisis, from commotion to commotion, from chaos to even more chaos". "Each and every one of these are methods to conceal poor performance and incompetence. If I were Wilders, I would lie awake at night thinking about it, because absolutely nothing has been achieved yet. In his words: a big zero." The reaction of the coalition and the cabinet after the riots in Amsterdam cannot count on a good word from Jetten. He saw politicians stoking the fire and escalating the matter instead of connecting. "The Netherlands is hungry for political leaders who do not polarize, but inspire. Who do not divide, but bring people together."

Identity Verification Market: USD 11.55B in 2023 to USD 39.73B by 2031